Cleerly LABS vs Zio XT ECG Monitoring System
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if you require a comprehensive, AI-powered assessment of coronary artery disease based on CCTA imaging. This tool is ideal for quantifying plaque burden, characterizing plaque types, and precisely measuring stenosis to inform personalized treatment strategies and track disease progression over time.
View Cleerly LABS →Choose Zio XT ECG Monitoring System if…
Choose the Zio XT ECG Monitoring System if you need to detect intermittent or asymptomatic cardiac arrhythmias over an extended period. This wearable, leadless device provides up to 14 days of continuous monitoring with high patient compliance, making it suitable for diagnosing elusive arrhythmias in patients with symptoms like palpitations or syncope.
View Zio XT ECG Monitoring System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | Zio XT ECG Monitoring System |
|---|---|---|
| Pricing | Varies | Contact for pricing |
| Deployment | Cloud, On-premise | Cloud-based (AWS EC2 platform), no on-premise hardware required. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Zio XT ECG Monitoring SystemTool B (Zio XT) offers superior patient usability due to its wearable, lead-free, water-resistant design, promoting high patient comfort and compliance for continuous monitoring. While Tool A (Cleerly LABS) provides a powerful web-based interface for clinicians, Tool B's patient-centric design makes it more accessible and less disruptive to daily life for the end-user.
Clinical Value
Cleerly LABSTool A (Cleerly LABS) provides a more comprehensive and proactive clinical value by offering detailed AI-powered analysis of coronary plaque characteristics, stenosis, and ischemia from CCTA, enabling personalized risk assessment and tracking of disease progression to prevent heart attacks. While Tool B (Zio XT) is excellent for arrhythmia detection, Cleerly's focus on structural disease and long-term prevention offers a broader impact on cardiovascular health management.
Pricing & Value
Zio XT ECG Monitoring SystemTool B (Zio XT) offers better pricing and value, with Medicare rates in the US ranging from approximately $229-$260.35 for up to 15 days of monitoring, and a UK cost of u00a3310 per patient. Tool A (Cleerly LABS) has a significantly higher cost per analysis, often resulting in $1000-$1500 out-of-pocket expenses when combined with the CCTA scan, making it less accessible for routine use.
Enterprise Readiness
Cleerly LABSBoth tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, and BAA agreements, operating on cloud-based AWS platforms. Tool A (Cleerly LABS) explicitly mentions integration with PACS, RIS, and EHR via an on-site proxy, which is crucial for seamless integration into existing hospital workflows. While Tool B (Zio XT) boasts no on-premise hardware, Cleerly's specific integration points give it a slight edge for established enterprise environments.
Innovation
Cleerly LABSTool A (Cleerly LABS) exhibits greater innovation by leveraging AI for a comprehensive, quantitative, and qualitative assessment of coronary plaque from CCTA, moving beyond traditional stenosis evaluation to characterize plaque volume and type. This advanced capability aims to redefine heart disease management by focusing on prevention and tracking disease progression, which is a significant leap in diagnostic imaging. Tool B (Zio XT) is also innovative with its long-term wearable ECG and AI analysis, but Cleerly's approach to understanding the underlying pathology of atherosclerosis is arguably more groundbreaking.
Support & Docs
TieNeither the provided structured facts nor readily available public information offer sufficient detail to differentiate between the two tools regarding the quality or availability of their support and documentation. Therefore, a tie is the most appropriate verdict for this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | Zio XT ECG Monitoring System |
|---|---|---|
| Tool Name | Cleerly LABS | Zio XT ECG Monitoring System |
| Company | Cleerly | iRhythm Technologies |
| Primary Technology/Methodology | AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) | Wearable, single-lead ECG biosensor for continuous cardiac monitoring, utilizing FDA-cleared AI and expert review |
| Core Function/Application | Detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. | Accurate arrhythmia detection and diagnosis through up to 14 days of continuous cardiac monitoring. |
| Key Output/Analysis | Comprehensive coronary plaque assessment (volume, type), stenosis detection and quantification, ischemia detection (with Cleerly ISCHEMIA module), 3D visualization, personalized heart disease risk assessment, tracking disease progression over time. | Arrhythmia detection and diagnosis, ECG data analysis, data reporting, patient-activated button for symptomatic event logging. |
| Data Acquisition Method/Duration | CCTA image analysis (single point in time, with ability to track progression over time). | Continuous ambulatory cardiac monitoring for up to 14 days via wearable biosensor. |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and Zio XT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or Zio XT ECG Monitoring System
Backers
Who funded each tool's parent company.